Bio & Pharma
NGeneBio to transfer NGS tech to UAE company
It will hand over the techs of diagnostic medical devices to Dubai-based Euro Alliance, with royalties for 10 years
By Apr 30, 2024 (Gmt+09:00)
1
Min read
Most Read
Samsung steps up AR race with advanced microdisplay for smart glasses


When in S. Korea, it’s a ritual: Foreigners make stops at CU, GS25, 7-Eleven


Maybe Happy Ending: A robot love story that rewrote Broadway playbook


NPS yet to schedule external manager selection; PE firms’ fundraising woes deepen


US auto parts tariffs take effect; Korea avoids heavy hit



South Korean medical diagnostic company NGeneBio Co. announced on Tuesday that it signed a contract with the United Arab Emirates (UAE)-based medical company Euro Alliance to transfer next-generation sequencing (NGS)-based precision diagnostic medical device manufacturing technology.
Euro Alliance is an investment and medical technology commercialization specialist company based in Switzerland and Dubai, the UAE. It conducts healthcare-related businesses in India as well.
Under the contract, NGeneBio will transfer NGS precision diagnostic products, analysis software, and production know-how to Euro Alliance in the UAE region.
The two companies will also establish a joint venture in India and the UAE for NGS business operations.
NGeneBio will receive royalties proportional to future sales over the 10 years as fees for the technology transfer. Meanwhile, Euro Alliance will handle business operations and infrastructure investments.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Bio & PharmaNGeneBio gets approval for cancer diagnostic device in Thailand
Dec 22, 2023 (Gmt+09:00)
1 Min read -
-
Bio & PharmaNGeneBio applies for US patent of early diagnosis tech of dementia
Sep 14, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaNGeneBio to launch precision cancer test service in Thailand
Feb 02, 2023 (Gmt+09:00)
1 Min read -
Comment 0
LOG IN